CYCLOSPORIN A (SANDIMMUN NEORAL) IN THERAPY FOR PSORIASIS AND PSORIATIC ARTHRITIS
The involvement of immune mechanisms in the pathogenesis of psoriatic arthritis (PA) is noted to give grounds to use immunoactive compounds (disease- modifying agents - basic anti-inflammatory drugs -BAIDs), such as cyclosporin A (CsA), in this disease. The data available in the literature permit a...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2010-09-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/307 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The involvement of immune mechanisms in the pathogenesis of psoriatic arthritis (PA) is noted to give grounds to use immunoactive compounds (disease- modifying agents - basic anti-inflammatory drugs -BAIDs), such as cyclosporin A (CsA), in this disease. The data available in the literature permit a high assessment of CsA as one of the BAIDs in the treatment of PA and psoriasis. CsA is stated to monitor the course of this disease, acts on inflamed peripheral joints, decreases the clinical and laboratory activity of PA, positively affects the PA-afflicted skin, and can induce remission of psoriasis. |
|---|---|
| ISSN: | 1996-7012 2310-158X |